M.V. Bluthgen - Concepedia

Author

M.V. Bluthgen

Also Known As

B. Virginia, Bluthgen Maria Virginia, Boccardi Virginia, J.N. Minatta, José Nicolas Minatta, M. Bluthgen, M.V. Bluthgen, Maria Virginia Bluthgen, Maria-Virginia Bluthgen, Marie-Virginia Bluthgen

Publications

743

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Inserm Université Paris-Saclay Université Paris-Sud Centre National de la Recherche Scientifique

About

M.V. Bluthgen is an author at Institut Gustave Roussy specializing in pathology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	612
2	Pathology	7	7	612
3	Immunology	2	2	42
4	Health Sciences	1	1	22
5	Cell Biology	1	1	90

M.V. Bluthgen

Publications

672

Citations

H-Index

Page 1

	Year	Citations
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort Oliver Gautschi, Julie Milia, Bastien Cabarrou, Journal of Thoracic Oncology MedicinePathologyEuropean Euraf CohortImmune Checkpoint InhibitorBronchial Neoplasm	2015	186
Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA Jordi Remón, Caroline Caramella, Cécile Jovelet, Annals of Oncology OncologyTumour DnaSomatic VariantOncogenic AgentMedicine	2017	162
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value Francesco Facchinetti, M.V. Bluthgen, Gabrielle Tergemina-Clain, Lung Cancer Somatic VariantLkb1/stk11 MutationsMedicinePrognostic ValuePathology	2017	110
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups Colin R. Lindsay, Vincent Faugeroux, Stefan Michiels, Annals of Oncology MedicinePathologyCancer GenomicsTumor Cell ProfilesProspective Examination	2017	90
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1 Isabelle Rouquette, Estelle Taranchon‐Clermont, Julia Gilhodes, Biomarker Research	2019	47
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience M.V. Bluthgen, C. Boutros, Florence Fayard, Lung Cancer Pretreated PatientsSingle-institution ExperienceMedicineImmunologyOral Etoposide	2016	27
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma Alison Dormieux, Laura Mezquita, Paul-Henry Cournède, European Radiology Tumor HeterogeneityMedicineMolecular StatusPathologyMetastatic Pattern	2020	22
Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC) J. Lahmar, Laura Mezquita, Serge Koscielny, Annals of Oncology Cancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsImmunologyPathology	2016	15
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study M.V. Bluthgen, Laura Faivre, Silvia Rosellini, Oncotarget	2017	13

Page 1